Immunomedics (IMMU) Reports Q1 Loss of $0.34
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Immunomedics Announces First Quarter Fiscal 2019 Results and Provides Corporate Update
November 7, 2018 4:05 PM ESTStrategic Manufacturing Partnership Entered into with Samsung BioLogics to Provide Anticipated Long-Term Supply of Sacituzumab Govitecan
Commercial Launch Preparations Nearing Completion with 50 Sales Representatives Recruited and in Training
Clinical Collaboration Agreement with AstraZeneca/MedImmune Expanded to Include Non-Small Cell Lung Cancer
MORRIS PLAINS, N.J., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Â Immunomedics, Inc.,... More



